These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34561554)

  • 1. Synergistic apoptotic effect of miR-183-5p and Polo-Like kinase 1 inhibitor NMS-P937 in breast cancer cells.
    Kudo M; Zalles N; Distefano R; Nigita G; Veneziano D; Gasparini P; Croce CM
    Cell Death Differ; 2022 Feb; 29(2):407-419. PubMed ID: 34561554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.
    Sero V; Tavanti E; Vella S; Hattinger CM; Fanelli M; Michelacci F; Versteeg R; Valsasina B; Gudeman B; Picci P; Serra M
    Invest New Drugs; 2014 Dec; 32(6):1167-80. PubMed ID: 25193492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
    Valsasina B; Beria I; Alli C; Alzani R; Avanzi N; Ballinari D; Cappella P; Caruso M; Casolaro A; Ciavolella A; Cucchi U; De Ponti A; Felder E; Fiorentini F; Galvani A; Gianellini LM; Giorgini ML; Isacchi A; Lansen J; Pesenti E; Rizzi S; Rocchetti M; Sola F; Moll J
    Mol Cancer Ther; 2012 Apr; 11(4):1006-16. PubMed ID: 22319201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polo-like kinase 1 inhibitor NMS-P937 represses nasopharyngeal carcinoma progression via induction of mitotic abnormalities.
    Gao J; Huang W; Zhao S; Wang R; Wang Z; Ye J; Lin L; Cai W; Mi Y
    J Biochem Mol Toxicol; 2024 Jan; 38(1):e23590. PubMed ID: 38037286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.
    Casolaro A; Golay J; Albanese C; Ceruti R; Patton V; Cribioli S; Pezzoni A; Losa M; Texido G; Giussani U; Marchesi F; Amboldi N; Valsasina B; Bungaro S; Cazzaniga G; Rambaldi A; Introna M; Pesenti E; Alzani R
    PLoS One; 2013; 8(3):e58424. PubMed ID: 23520509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-509-3-5p causes aberrant mitosis and anti-proliferative effect by suppression of PLK1 in human lung cancer A549 cells.
    Wang XH; Lu Y; Liang JJ; Cao JX; Jin YQ; An GS; Ni JH; Jia HT; Li SY
    Biochem Biophys Res Commun; 2016 Sep; 478(2):676-82. PubMed ID: 27498003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of PLK1 through competition between hnRNPK, miR-149-3p and miR-193b-5p.
    Shin CH; Lee H; Kim HR; Choi KH; Joung JG; Kim HH
    Cell Death Differ; 2017 Nov; 24(11):1861-1871. PubMed ID: 28708135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer.
    Xu C; Li S; Chen T; Hu H; Ding C; Xu Z; Chen J; Liu Z; Lei Z; Zhang HT; Li C; Zhao J
    Oncol Rep; 2016 Jan; 35(1):497-503. PubMed ID: 26549165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-296-5p suppresses papillary thyroid carcinoma cell growth via targeting PLK1.
    Zhou SL; Tang QL; Zhou SX; Ren RZ
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2084-2091. PubMed ID: 30915753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.
    Liu J; Lu KH; Liu ZL; Sun M; De W; Wang ZX
    BMC Cancer; 2012 Nov; 12():519. PubMed ID: 23151088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
    Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B
    Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
    Hu K; Law JH; Fotovati A; Dunn SE
    Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer.
    Ito T; Sato F; Kan T; Cheng Y; David S; Agarwal R; Paun BC; Jin Z; Olaru AV; Hamilton JP; Selaru FM; Yang J; Matsumura N; Shimizu K; Abraham JM; Shimada Y; Mori Y; Meltzer SJ
    Int J Cancer; 2011 Nov; 129(9):2134-46. PubMed ID: 21170987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A miR-361-5p/ ORC6/ PLK1 axis regulates prostate cancer progression.
    Liu Z; Zhang Y; Yu L; Zhang Z; Li G
    Exp Cell Res; 2024 Jul; 440(1):114130. PubMed ID: 38885805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-593-5p promotes the development of hypoxic-induced pulmonary hypertension via targeting PLK1.
    Zhao TF; Wang SY; Zou XZ; Zhao HD
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3495-3502. PubMed ID: 31081105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells.
    Hartsink-Segers SA; Exalto C; Allen M; Williamson D; Clifford SC; Horstmann M; Caron HN; Pieters R; Den Boer ML
    Haematologica; 2013 Oct; 98(10):1539-46. PubMed ID: 23753023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-593-5p inhibit cell proliferation by targeting PLK1 in non small cell lung cancer cells.
    Yan L; Zhang Y; Li K; Wang M; Li J; Qi Z; Wu J; Wang Z; Ling L; Liu H; Wu Y; Lu X; Xu L; Zhu Y; Zhang Y
    Pathol Res Pract; 2020 Feb; 216(2):152786. PubMed ID: 31864714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
    Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA DANCR improves the dysfunction of the intestinal barrier and alleviates epithelial injury by targeting the miR-1306-5p/PLK1 axis in sepsis.
    Wang Z; Zhong C; Cao Y; Yin H; Shen G; Lu W; Ding W
    Cell Biol Int; 2021 Sep; 45(9):1935-1944. PubMed ID: 34003569
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Zhu J; Cui K; Cui Y; Ma C; Zhang Z
    DNA Cell Biol; 2020 May; 39(5):747-755. PubMed ID: 32182129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.